scholarly journals Cost-effectiveness of dengue vaccination in Puerto Rico

2021 ◽  
Vol 15 (7) ◽  
pp. e0009606
Author(s):  
Guido España ◽  
Andrew J. Leidner ◽  
Stephen H. Waterman ◽  
T. Alex Perkins
Keyword(s):  
Puerto Rico ◽  
Cost Effectiveness ◽  
Virus Infection ◽  
Dengue Virus ◽  
Control Measure ◽  
Severe Disease ◽  
Base Case ◽  
Dengue Virus Infection ◽  
False Positive Test ◽  
The Cost

An effective and widely used vaccine could reduce the burden of dengue virus (DENV) around the world. DENV is endemic in Puerto Rico, where the dengue vaccine CYD-TDV is currently under consideration as a control measure. CYD-TDV has demonstrated efficacy in clinical trials in vaccinees who had prior dengue virus infection. However, in vaccinees who had no prior dengue virus infection, the vaccine had a modestly elevated risk of hospitalization and severe disease. The WHO therefore recommended a strategy of pre-vaccination screening and vaccination of seropositive persons. To estimate the cost-effectiveness and benefits of this intervention (i.e., screening and vaccination of seropositive persons) in Puerto Rico, we simulated 10 years of the intervention in 9-year-olds using an agent-based model. Across the entire population, we found that 5.5% (4.6%-6.3%) of dengue hospitalizations could be averted. However, we also found that 0.057 (0.045–0.073) additional hospitalizations could occur for every 1,000 people in Puerto Rico due to DENV-naïve children who were vaccinated following a false-positive test results for prior exposure. The ratio of the averted hospitalizations among all vaccinees to additional hospitalizations among DENV-naïve vaccinees was estimated to be 19 (13–24). At a base case cost of vaccination of 382 USD, we found an incremental cost-effectiveness ratio of 122,000 USD per QALY gained. Our estimates can provide information for considerations to introduce the CYD-TDV vaccine in Puerto Rico.

scholarly journals Cost-effectiveness of Dengue Vaccination in Puerto Rico

2020 ◽  
Author(s):  
Guido España ◽  
Andrew J. Leidner ◽  
Stephen Waterman ◽  
T. Alex Perkins
Keyword(s):  
Puerto Rico ◽  
Cost Effectiveness ◽  
Control Measure ◽  
Severe Disease ◽  
Dengue Infection ◽  
Base Case ◽  
Test Results ◽  
Agent Based ◽  
False Positive Test ◽  
The Cost

ABSTRACTAn effective and widely used vaccine could reduce the burden of dengue virus (DENV) around the world. DENV is endemic in Puerto Rico, where the dengue vaccine CYD-TDV is currently under consideration as a control measure. CYD-TDV has demonstrated efficacy in clinical trials in vaccinees who had prior dengue infection. However, in vaccinees who had no prior dengue infection, the vaccine had a modestly elevated risk of hospitalization and severe disease. The WHO therefore recommended a strategy of pre-vaccination screening and vaccination of seropositive persons. To estimate the cost-effectiveness and benefits of this intervention (i.e., screening and vaccination of seropositive persons) in Puerto Rico, we simulated 10 years of the intervention in 9-year-olds using an agent-based model. Across the entire population, we found that 5.5% (4.6%-6.3%) of dengue hospitalizations could be averted. However, we also found that 1.6 (1.3 - 2.1) additional hospitalizations could occur for every 1,000 DENV-naïve children who were vaccinated following a false-positive test results for prior exposure. The ratio of the averted hospitalizations among all vaccinees to additional hospitalizations among DENV-naïve vaccinees was estimated to be 19 (13-24). At a base case cost of vaccination of 382 USD, we found an incremental cost-effectiveness ratio of 122,000 USD per QALY gained. Our estimates can provide information for considerations to introduce the CYD-TDV vaccine in Puerto Rico.

Lost in post-translational modification—Dengue virus writes its own sequel

2021 ◽  
Vol 6 (61) ◽  
pp. eabk1555
Author(s):  
Soumya S. Yandamuri ◽  
Kevin C. O’Connor
Keyword(s):  
Virus Infection ◽  
Dengue Virus ◽  
Severe Disease ◽  
Post Translational Modification ◽  
Dengue Virus Infection ◽  
Elevated Frequency ◽  
Prior Infection

Elevated frequency of afucosylated IgG1 antibodies during dengue virus infection is associated with prior infection and predicts severe disease.

scholarly journals Sero-diagnosis of Dengue virus in Different Hospitals of Nepal

2013 ◽  
Vol 1 (2) ◽  
pp. 58-62 ◽  
Author(s):  
Y Shah ◽  
G Khadka ◽  
GP Gupta ◽  
N Adhikari ◽  
A Poudel ◽  
...  
Keyword(s):  
Virus Infection ◽  
Dengue Virus ◽  
Dengue Fever ◽  
Control Measure ◽  
Public Health Problem ◽  
Enzyme Linked Immunosorbent Assay ◽  
Dengue Virus Infection ◽  
Capture Elisa ◽  
Occupation Group ◽  
Hilly Region

INTRODUCTION: Dengue fever (DF) is an emerging mosquito borne viral disease and important public health problem in low land Terai region which is also moving towards hilly region Nepal. This study was designed to determine the sero-prevalence of dengue virus infection in patients visiting hospitals of Nepal. MATERIALS AND METHODS: This study was conducted during period (June-November) of 2010 in Nepalese patients with fever visiting hospitals of Birganj, Damouli, Biratanagar, Dhading Besi and Chitwan. The sero-prevalence of dengue virus specific IgM was determined by enzyme linked immunosorbent assay (ELISA). Serum samples were collected from 289 patients visiting hospitals with history of fever and clinically suspected dengue fever. RESULTS: The anti-dengue IgM positivity was found to be 8.99%. The positive dengue cases were higher in male (10.8%) as compared to female (7.1%) though it was not statistically significant (P>0.05). Among different age groups, the highest positive cases (12.3%) were from age group below 15 years followed by above 50 years 8.3%. Out of 5 hospitals, the highest positive cases were in Tanahu hospital, Damouli (23.8%) followed by Bharatpur hospital and Chitwan (22.2%). Age and gender were found to be independent predictors. The highest numbers of dengue positive cases were in occupation group business (13.3%) followed by agriculture (12.7%). CONCLUSIONS: Prevalence of dengue virus infection is increasing and proper control measure should be provided. IgM capture ELISA was used for laboratory analysis and remains as a reliable and inexpensive method for the diagnosis of dengue. Hence, the IgM capture ELISA has become the most accepted technique for the diagnosis of dengue in developing countries like Nepal. DOI: http://dx.doi.org/10.3126/ijim.v1i2.7003 Int J Infect Microbiol 2012;1(1):58-62

scholarly journals Incidence of Dengue Virus Infection in School-Aged Children in Puerto Rico: A Prospective Seroepidemiologic Study

2015 ◽  
Vol 92 (3) ◽  
pp. 486-491 ◽  
Author(s):  
D. Fermín Argüello ◽  
Kay M. Tomashek ◽  
Elizabeth Hunsperger ◽  
Luz Acosta ◽  
Christine Luxemburger ◽  
...  
Keyword(s):  
Puerto Rico ◽  
Virus Infection ◽  
Dengue Virus ◽  
Dengue Virus Infection ◽  
School Aged Children ◽  
Seroepidemiologic Study

scholarly journals Dengue Virus Infection of Blood–Brain Barrier Cells: Consequences of Severe Disease

2019 ◽  
Vol 10 ◽  
Author(s):  
María-Angélica Calderón-Peláez ◽  
Myriam L. Velandia-Romero ◽  
Leidy Y. Bastidas-Legarda ◽  
Edgar O. Beltrán ◽  
Sigrid J. Camacho-Ortega ◽  
...  
Keyword(s):  
Virus Infection ◽  
Dengue Virus ◽  
Blood Brain Barrier ◽  
Severe Disease ◽  
Brain Barrier ◽  
Dengue Virus Infection ◽  
Blood Brain

scholarly journals Aberrant monocyte responses predict and characterize dengue virus infection in individuals with severe disease

2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Yean K. Yong ◽  
Hong Y. Tan ◽  
Soe Hui Jen ◽  
Esaki M. Shankar ◽  
Santha K. Natkunam ◽  
...  
Keyword(s):  
Virus Infection ◽  
Dengue Virus ◽  
Severe Disease ◽  
Dengue Virus Infection

scholarly journals Serotype and Clinical Performance of Dengue Virus Infection on the Year 2009

2010 ◽  
Vol 1 (2) ◽  
pp. 55 ◽  
Author(s):  
Soegeng Soegijanto ◽  
Widodo Darmowandowo ◽  
Amor Peraten Ginting ◽  
Atsushi Yamanaka
Keyword(s):  
Virus Infection ◽  
Dengue Virus ◽  
Clinical Manifestation ◽  
Clinical Performance ◽  
Secondary Infection ◽  
Severe Disease ◽  
Dengue Shock Syndrome ◽  
Severe Dengue ◽  
Rt Pcr ◽  
Dengue Virus Infection

Dengue hemorrhagic fever is one of the important health problem in Indonesia, mortality rate is becoming decrease but many dengue shock syndrome cases is very difficult to be help. Previous study showed that some of DEN 2 and DEN 3 virus cases could show a clinical performance of severe dengue virus infection such as dengue shock syndrome. There are four serotype of dengue virus infection can cause primary and secondary infection. The aim of this research is to know the relationship between clinical performance of dengue virus infection and serotype dengue virus and also to know the role of primary and secondary infection and age of dengue virus cases. A prospective analytic observational study, which was conducted in Dr. Soetomo hospital since January 2009. RT-PCR was used to attempt to identify the infecting serotype from dengue virus isolated using vero cell. Antibody responses were measured by ELISA and clinical manifestation were measured with the WHO criteria 1997. Dengue serotype identification by RT-PCR was 70 patients. Virus types were DEN-2 65(92.8%), DEN-1 3(4.2%), and DEN-3 2(2.8%). Patients with DEN-1 genotype IV were more trend severe disease DSS and unusual infection. Commanly usually secondary exposure cause more severe clinical manifestation than primary exposure (p = 0.035) but in this study found that all of DEN-1 genotype IV, primary or secondary infection to show severe clinical manifestation of dengue virus infection. We can conclude that DEN-2 was the most dominant serotype in Dr. Soetomo Hospital. On Primary and secondary infection, DEN-1 genotype IV showing more severe than DEN-2 and DEN-3.

scholarly journals Upregulation of SCUBE1 in Dengue Virus Infection

2019 ◽  
Vol 7 (10) ◽  
pp. 1602-1607
Author(s):  
Hirowati Ali ◽  
Coyza Prana ◽  
Ellyza Nasrul
Keyword(s):  
Virus Infection ◽  
Dengue Virus ◽  
Early Recognition ◽  
Communicable Disease ◽  
Severe Disease ◽  
World Health ◽  
Healthy Controls ◽  
Dengue Virus Infection ◽  
Laboratory Parameters ◽  
Inflammatory Conditions

BACKGROUND: Dengue is a major communicable disease in tropical areas, with an increasing prevalence every year. Thrombocytopenia is one of the commonly used laboratory parameters for predicting the severity of the disease. It is detected on day 6 or day 7 after the febrile stage, and its presence indicates that the disease has become potentially fatal. Therefore, it is necessary to identify a marker for the early recognition of dengue virus infection during the febrile stage before the detection of thrombocytopenia on day 6 to prevent severe disease outcomes. Signal peptide-CUB- (complement C1r/C1s)-EGF (epidermal growth factor)-like domain-containing protein 1 (SCUBE1) is secreted in activated platelets under inflammatory conditions and enhances platelet-platelet adhesion and agglutination. This gene was first identified in human vascular endothelium, but its biological role in platelets remains unknown. AIM: This study aims to identify SCUBE1 expression during the febrile stage of dengue virus infection and examine the correlation of its expression with thrombocytopenia occurrence on day 6. MATERIAL AND METHODS: Blood samples were collected from 17 patients infected with dengue virus on day-3 fever and from 16 healthy controls who met the inclusion and exclusion criteria for dengue virus infection according to the World Health Organization (WHO) classification for dengue virus infection. All samples were subjected to SCUBE1 gene analysis using real-time reverse transcription quantitative PCR (RT-PCR). RESULTS: The results showed that upregulation of SCUBE1 gene in infected patients (8.9 ± 3.1-fold) compared to that in healthy controls, indicating SCUBE1 involvement in dengue virus infection. Furthermore, we analysed the laboratory parameters of infected patients on day 3 and day 6, when thrombocytopenia is usually detected. Platelet count was found to be significantly decreased from day 3 until day 6 in the infected patients. Unfortunately, our results showed no correlation between SCUBE1 expression in the febrile stage and the occurrence of thrombocytopenia on day 6. CONCLUSION: The conclusion of this study is SCUBE1 might play a role in dengue virus infection but does not correlate with thrombocytopenia on day-6 fever.

Sign in / Sign up

Export Citation Format

Share Document